Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201303052417N11

Enrollment

Registered

2013-06-12

Start date

2012-11-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease. End Stage Renal Disease

Interventions

Intervention 1: Cap Omega-3 1000mg 3capsule per day for 2 months manufactured by Zahravi company. Intervention 2: Cap placebo for 2 months manufactured by Zahravi company.

Treatment - Drugs

Placebo

Cap Omega-3 1000mg 3capsule per day for 2 months manufactured by Zahravi company

Cap placebo for 2 months manufactured by Zahravi company

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: 1- age more than 18 years old. 2- peritoneal dialysis for 3 months at least. Exclusion criteria: 1- history of malignancy. 2- steatorhea. 3- thrombocytopenia (platelet less than 100000/mm3). 4- coagulopathy. 5- anticoagulation therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum Interlukin-6 level. Timepoint: Begining of the study, after 2 months. Method of measurement: ELISA Kit pg/mL.;Serum CRP level. Timepoint: Begining of the study, after 2 months. Method of measurement: ELISA Kit, mg/L.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Firouzeh Moeinzadeh

University of Medical Sciences

moinzade@resident.mui.ac.ir+98 31 1625 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026